Pfizer Collaborative Agreement
The University of Colorado and Pfizer, Inc. have formed a new partnership to accelerate the translation of biomedical research into effective drug targets and therapies for patients. The agreement funds research projects and postdoctoral fellowships in the biosciences. The collaboration between the two organizations is designed to reduce the time and cost to translate biomedical research into new medications and therapies.
Anticipated project funding from this program will average $200,000 to $250,000 per year, with an expected range from $50,000 to $500,000 per year for approximately two years. Final numbers are dependent on the fit between the submitted proposals with Pfizer’s research interests. The agreement was set up through the newly established Office of Industry Collaboration at CU-Boulder.
Pfizer is looking for academic researchers who are focused on new approaches to cancer diagnoses; on tools and drugs for cardiovascular, neurodegenerative and neuropsychiatric diseases; and methods for evaluating the effectiveness of drugs. Because the agreement is flexible, researchers focused on other biomedical areas are also encouraged to submit a concept.
- It's important that you know Pfizer will obtain certain intellectual property rights on the work paid for by Pfizer. This includes patentable and non-patentable discoveries, as well as software, data and other copyrighted materials. Please check with regarding specific questions you may have. They understand the details of this agreement and will help you determine if this opportunity is right for you.
- Know that there is a rolling deadline for the concept submission, so please feel free to submit at any time.